[Click eStock] "Voronoi, Clinical Trial Disclosure Faster Than Expected"

Yuanta Securities analyzed on the 4th that Voronoi will disclose the clinical results of the EGFR non-small cell lung cancer targeted therapy (VRN11) faster than expected.

Hyunsoo Ha, a researcher at Yuanta Securities, said, "The first clinical results of VRN11, which were expected to be disclosed at ASCO at the end of May this year, will be disclosed at the American Association for Cancer Research (AACR 2025) at the end of next month," adding, "Considering that data will be presented at various conferences, it is estimated that the clinical trials are progressing rapidly."

He continued, "Following a significant increase in the number of patients in phase 1 from 50 to 103 last year, the target dosage at the beginning of the year was also increased from a maximum of 160mg to over 320mg," adding, "Considering the regulatory agency's approval of the change, it is expected that an excellent safety profile was shown in the initial cohort."

Researcher Ha analyzed, "The target price is raised from the previous 160,000 KRW to 240,000 KRW," and added, "The target price increase reflects the value of VRN11 as a first-line treatment." He also emphasized, "The value of the first-line treatment only reflects the value for patients with CNS metastasis," and "Since the effectiveness of existing treatments is declining in CNS metastasis, accelerated approval is also possible."

He said, "Starting with this year's AACR, multiple clinical results of VRN11 and VRN07 will be announced," and added, "The disclosure of clinical data is expected to be a strong driving force for stock price increases."